Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Alexandra Albertsson Lindblad"'
Autor:
Kossi D. Abalo, Sara Ekberg, Therese M. L. Andersson, Simon Pahnke, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Ingrid Glimelius
Publikováno v:
HemaSphere, Vol 8, Iss 7, Pp n/a-n/a (2024)
Abstract Advancements in treatments have significantly improved the prognosis for mantle cell lymphoma (MCL), and there is a growing population of survivors with an increased susceptibility to infections. We assessed the incidence of infections by cl
Externí odkaz:
https://doaj.org/article/21cce12d5c1242128c67c1e9b23f2133
Autor:
Mats Jerkeman, Sara Ekberg, Ingrid Glimelius, Alexandra Albertsson-Lindblad, Joshua P. Entrop, Fredrik Ellin, Kristina Sonnevi, Catharina Lewerin, Lena Brandefors, Karin E. Smedby
Publikováno v:
HemaSphere, Vol 7, Iss 8, p e928 (2023)
Mantle cell lymphoma (MCL) is a B-cell malignancy currently considered incurable. Although some patients obtain prolonged remission after first-line chemoimmunotherapy, many will need several treatment lines. Here, we present a nationwide assessment
Externí odkaz:
https://doaj.org/article/35ed8116516c469c8ec483f8432db57d
Autor:
Alexandra Albertsson-Lindblad, Thorgerdur Palsdottir, Karin E. Smedby, Caroline E. Weibull, Ingrid Glimelius, Mats Jerkeman
Publikováno v:
Haematologica, Vol 107, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/5c626f26f1574e8c830231d64d71a51a
Publikováno v:
Experimental Hematology & Oncology, Vol 8, Iss 1, Pp 1-5 (2019)
Abstract Background The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antibody-dependent cellu
Externí odkaz:
https://doaj.org/article/d4b9ec25f0164c6d9d530f9370e4230e
Autor:
Christian Winther Eskelund, Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Lone Bredo Pedersen, Christian Hartmann Geisler, Mats Jerkeman, Kirsten Grønbæk
Publikováno v:
Haematologica, Vol 103, Iss 11 (2018)
Externí odkaz:
https://doaj.org/article/010fd38a51c04e03a49a39f12c42a243
Autor:
Sara, Ekberg, Karin, Ekström Smedby, Alexandra, Albertsson-Lindblad, Mats, Jerkeman, Caroline E, Weibull, Ingrid, Glimelius
Publikováno v:
Blood advances.
Studies on late effects in mantle cell lymphoma (MCL) patients are increasingly important as survival is improving and novel targeted drugs are being introduced, however knowledge about late effects is limited. The aim of this population-based study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e0b66f3aeabb9998d5a0395eecddf385
https://pubmed.ncbi.nlm.nih.gov/35973196
https://pubmed.ncbi.nlm.nih.gov/35973196
Autor:
Alexandra Albertsson-Lindblad, Christian Winther Eskelund, Åsa Lindberg, Arne Kolstad, Christian H. Geisler, Kirsten Grønbæk, Riikka Räty, Anna Laurell, Mats Jerkeman
Publikováno v:
Lindberg, Å, Eskelund, C W, Albertsson-Lindblad, A, Kolstad, A, Laurell, A, Räty, R, Grønbæk, K, Geisler, C H & Jerkeman, M 2022, ' Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma : The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience ', Hematological Oncology, vol. 40, no. 1, pp. 23-31 . https://doi.org/10.1002/hon.2940
Mantle cell lymphoma (MCL) is a rare, often aggressive type of B-cell lymphoma with poor survival and no cure. Cancer and cancer treatment has a negative impact on health-related quality of life (HRQOL) both during active disease and in the long term
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5447dfa3636f368fa37f8a1294d4f8
https://curis.ku.dk/portal/da/publications/pretreatment-healthrelated-quality-of-life-parameters-have-prognostic-impact-in-patients-65years-with-newly-diagnosed-mantle-cell-lymphoma(6355d860-2b80-4a1f-a904-05e5a772f03d).html
https://curis.ku.dk/portal/da/publications/pretreatment-healthrelated-quality-of-life-parameters-have-prognostic-impact-in-patients-65years-with-newly-diagnosed-mantle-cell-lymphoma(6355d860-2b80-4a1f-a904-05e5a772f03d).html
Autor:
null Åsa Lindberg, null Christian Winther Eskelund, null Alexandra Albertsson‐Lindblad, null Arne Kolstad, null Anna Laurell, null Riikka Räty, null Kirsten Grønbæk, null Christian Hartmann Geisler, null Mats Jerkeman
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7769f72fef003113031dfe335d1d753
https://doi.org/10.1002/hon.2940/v2/response1
https://doi.org/10.1002/hon.2940/v2/response1
Autor:
Ingrid, Glimelius, Karin E, Smedby, Alexandra, Albertsson-Lindblad, Michael J, Crowther, Sandra, Eloranta, Mats, Jerkeman, Caroline E, Weibull
Publikováno v:
Blood Adv
It is unknown how many mantle cell lymphoma (MCL) patients undergo consolidation with autologous hematopoietic cell transplantation (AHCT), and the reasons governing the decision, are also unknown. The prognostic impact of omitting AHCT is also under
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ebfd52236e4ded6d52177e197e963659
https://pubmed.ncbi.nlm.nih.gov/33710334
https://pubmed.ncbi.nlm.nih.gov/33710334
Autor:
Caroline E. Weibull, Sara Ekberg, Karin E. Smedby, Ingrid Glimelius, Alexandra Albertsson-Lindblad, Mats Jerkeman
Publikováno v:
Blood. 138:1344-1344
Purpose The improved survival for mantle cell lymphoma (MCL) patients calls for updated knowledge about long-term adverse effects of treatment. We recently showed that younger MCL patients (≤65 years of age) selected for rituximab-cytarabine contai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77fc894afababc90cd23650c895e3868
https://doi.org/10.1182/blood-2021-145450
https://doi.org/10.1182/blood-2021-145450